The
global market for cancer therapeutics and supportive care drugs was valued at
around USD 117.8 billion in 2016 and is expected to reach USD 222.9 billion by
2023, growing at a CAGR of around 9.7% during the forecast period of 2017 to
2023. Cancer, also called malignancy, is an abnormal growth of cells. There are
more than 100 types of cancer, including breast cancer, skin cancer, lung
cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on
the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.
2015 year saw a new high in the number of US food and drug administration
approvals of new pharmaceuticals, including new molecular entities (NMEs) and
new Biologic License Applications (BLAs), amounting to a total of 45 NMEs and
BLAs in all disease states compared with 41 approved in 2014 and much fewer
(27) in 2013. Of these 45 NMEs and BLAs entering the market last year, 16 were
novel therapies for cancer, providing patients new hope through novel treatment
options and new mechanisms of action. New trends in oncology drug development
are reflected in the increasing use of biotechnology in the development of
anticancer drugs, including immunotherapies or monoclonal antibodies,
adoptive-cell therapies, and new vaccines.

New
treatment options have become available in the past five years, and the surge
of innovation is expected to continue due to a robust pipeline of drugs in
clinical development by a large and diverse group of pharmaceutical companies.
Innovations in the development of new drugs and therapies, large number of new
drugs entering into the market with FDA approval, increasing prevalence of
cancerous patients, availability of new treatment options in the market
and rise in base of aging population are the key driving factors for the growth
of this market. In addition, changing lifestyle habits of populations,
increased patient’s healthcare awareness, and increasing demand for non-invasive
therapies are further expected to propel the market growth in the coming years.
Along with these driving factors, the market for cancer therapeutics is
facing some challenges such as time consuming regulatory compliance and high
cost of cancer drugs. However, the market for cancer therapeutics and
supportive care drugs is likely to rise in the future due to the large number
of ongoing innovations for the treatment of cancer.

Geographically,
North America is the leading contributor to the market and is expected to
retain its position during the forecast period due to high awareness, presence
of large base of cancer patients, rise in investments, and various initiatives
by government in the healthcare sector. However, Asia-Pacific market is expected
to grow at a faster rate during the forecast period. This is predominantly due
to increased healthcare awareness, technological advancements, significant
investments and growing awareness among the population about the treatment
options available in the market.

Companies
profiled:

Abbott
Laboratories,

AstraZeneca
plc,

Astellas
Pharma Inc.,

Bristol-Myers
Squibb,

Johnson
& Johnson,

Eli Lilly,

Novartis,

Pfizer Inc.,

Sanofi,
AbbVie, Inc.,

Teva
Pharmaceuticals,

Takeda
Pharmaceuticals, etc.

Report
Highlights:

The
report delivers a strategic analysis of the global market for cancer
therapeutics and supportive care drugs and growth forecast for the period from
2017 – 2023. The scope of the report includes competitive analysis of various
market players who are operating in the market, segmental analysis based on
type. It also covers geographical analysis of the market with growth forecast
for the period of 2017– 2023. The Porter’s Five Forces analysis and value chain
analysis included in the report provides an insight into market dynamics and
industry competition.

Moreover,
the report also includes growth strategies and entry barriers to be considered
to cater to the exact business opportunities in this market. Additionally, to
aid in strategic decision making, the report also includes competitive
profiling of leading players, recent developments in the industry and various
business strategies adopted by them. This report will help players in global
cancer therapeutics market to plan and implement their strategies in different
market areas such as emerging geographies, and new technologies.

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.